Tatum W O, Galvez R, Benbadis S, Carrazana E
Department of Neurology, Tampa General Hospital, University of South Florida, USA.
Arch Fam Med. 2000 Nov-Dec;9(10):1135-41. doi: 10.1001/archfami.9.10.1135.
There has been an explosion of new antiepileptic drug availability for physicians to treat patients with recurrent seizures. Principal antiepileptic drugs consisted of 6 key agents for both generalized and partial epilepsy for nearly 8 decades. Since 1993, the availability of newer "second-generation" agents has nearly doubled the armamentarium available for the 2.5 million patients who have recurrent seizures. This new influx of medications has flooded the medical and lay community with choices never before appreciated. The promise of improved tolerability with different safety and efficacy profiles has been exciting for all involved in epilepsy management. While most of the newer agents have been approved for adjunctive use in medically refractory partial epilepsy with recurrent complex partial and secondarily generalized seizures, efficacy is expanding to include generalized epilepsy and children for some agents. Arch Fam Med. 2000;9:1135-1141
可供医生用于治疗复发性癫痫患者的新型抗癫痫药物激增。在近80年的时间里，主要的抗癫痫药物由6种用于全身性和部分性癫痫的关键药物组成。自1993年以来，新型“第二代”药物的出现，使可供250万患有复发性癫痫的患者使用的药物种类几乎增加了一倍。这种新涌入的药物为医疗界和普通大众带来了前所未有的选择。对于所有参与癫痫治疗的人来说，具有不同安全性和疗效特征的更好耐受性的前景令人兴奋。虽然大多数新型药物已被批准用于辅助治疗药物难治性部分性癫痫伴复发性复杂部分性发作和继发性全身性发作，但有些药物的疗效正在扩展到全身性癫痫和儿童。《家庭医学文献》。2000年；9：1135 - 1141
